Unless otherwise stated, all abbreviations used herein shall have the same meaning as those mentioned in the announcement dated 2 December 2020 in relation to the Collaborative Agreement (“Announcement”).

The Board of Directors of Bioalpha Holdings Berhad (“Bioalpha” or “the Company”) wishes to inform that the Company has received Bursa Malaysia Securities Berhad’s request dated 4 December 2020 for additional information in relation to the Company’s announcement made on 2 December 2020. The additional information are as follows:

1.           The commencement and expiry dates of the Collaborative Agreement and whether the Collaborative Agreement is subject to renewal, and if yes, the details of such renewal.

The Collaborative Agreement (“CA”) has commenced on 2 December 2020 for the initial contract period of 5 years (“Initial Contract Period”). The CA may be extended for a further period of 5 years to be mutually agreed by both Parties.

2.           The risks in relation to the Collaboration Agreement.

Bioalpha does not expect any material risk arising from the CA other than the normal operational risk associated with the CA, which Bioalpha would take appropriate measures to mitigate.

3.           The financial effect of the Collaborative Agreement on the earning per share of the Group.

Barring any unforeseen circumstances, the Board envisages the CA to contribute positively to the earnings per share of Bioalpha in the future.

This announcement is dated 4 December 2020.